Wells Fargo lowered the firm’s price target on RxSight (RXST) to $17 from $22 and keeps an Equal Weight rating on the shares following the conference call to discuss the preliminary Q1 2025 sales results and lowered FY25 guidance. The company called out weak LAL volume trends through Q1, especially March, competitive product launches, and recessionary concerns, Wells notes.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RXST:
- RxSight downgraded to Underweight from Overweight at JPMorgan
- Stocks plummet after Trump tariffs, JPMorgan warns of recession: Morning Buzz
- Block upgraded, Nvidia downgraded: Wall Street’s top analyst calls
- RxSight double downgraded to Underperform at BofA after FY25 guidance cut
- RxSight downgraded to Underperform from Buy at BofA